Brian M. Watson

Robust Central Reduction of Amyloid-β in Humans with an Orally Available, Non-Peptidic β-Secretase Inhibitor

Patrick C. May, Robert A. Dean, Stephen L. Lowe et al. · Journal of Neuroscience · 2011 · 365 citations · Full text

Robust Central Reduction, Amyloid-β Peptide, Neurochemical Biomarkers +21

The Potent BACE1 Inhibitor LY2886721 Elicits Robust Central Aβ Pharmacodynamic Responses in Mice, Dogs, and Humans

Patrick C. May, Brian A. Willis, Stephen L. Lowe et al. · Journal of Neuroscience · 2015 · 195 citations · Full text

Amyloid β, Neurodegenerative Diseases, Amyloid Lowering +15

3-Aminoquinazolinediones as a New Class of Antibacterial Agents Demonstrating Excellent Antibacterial Activity Against Wild-Type and Multidrug Resistant Organisms

Edmund L. Ellsworth, Tuan P. Tran, Hollis D. Showalter et al. · Journal of Medicinal Chemistry · 2006 · 62 citations · Full text

Bioorganic Chemistry, Antiparasitic Agent, Antibiotic Adjuvant +19

Synthesis and Pharmacological Characterization of 2-(2,6-Dichlorophenyl)-1-((1<i>S</i>,3<i>R</i>)-5-(3-hydroxy-3-methylbutyl)-3-(hydroxymethyl)-1-methyl-3,4-dihydroisoquinolin-2(1<i>H</i>)-yl)ethan-1-one (LY3154207), a Potent, Subtype Selective, and Orally Available Positive Allosteric Modulator of the Human Dopamine D1 Receptor

Junliang Hao, James P. Beck, John M. Schaus et al. · Journal of Medicinal Chemistry · 2019 · 56 citations · Full text

Pharmacological Characterization, Drug Target, Pharmacotherapy +21

Structure–activity relationships of 3-aminoquinazolinediones, a new class of bacterial type-2 topoisomerase (DNA gyrase and topo IV) inhibitors

Tuan P. Tran, Edmund L. Ellsworth, Joseph P. Sanchez et al. · Bioorganic & Medicinal Chemistry Letters · 2006 · 51 citations

Molecular Pharmacology, Antimicrobial Drug Discovery, Biochemistry +12